ALS 2158

Drug Profile

ALS 2158

Alternative Names: ALS-002158; ALS-2158

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Vertex Pharmaceuticals
  • Class Adenine nucleotides; Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 25 Sep 2012 Discontinued - Phase-I for Hepatitis C (treatment-naive patients) in Australia (PO)
  • 25 Sep 2012 Discontinued - Phase-I for Hepatitis C (treatment-naive patients) in New Zealand (PO)
  • 09 Dec 2011 Phase-I clinical trials in Hepatitis C (treatment-naive patients) in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top